SNP genotyping → variant-to-pathway mapping → personalized macro/micronutrient prescription, validated against longitudinal biomarker response
Nutrigenomics begins with accurate, reproducible genotyping of single-nucleotide polymorphisms (SNPs) known to modulate nutrient metabolism. Consumer and clinical panels typically use SNP microarrays rather than full whole-genome sequencing, trading comprehensive coverage for cost (~$50-150) and turnaround (3-10 days) while still capturing the handful of well-replicated nutrition-relevant loci.
Sample collection & DNA extraction: • Saliva (Oragene kit) or buccal swab; yields 2–10 µg genomic DNA • Silica-column extraction; A260/280 ratio 1.7–2.0 required for array hybridization
Microarray genotyping (Illumina Infinium chemistry): • Whole-genome amplification → fragmentation → hybridization to bead-bound 50-mer probes • Single-base extension with labeled ddNTP → fluorescence read by iScan • ~650,000 probes per array; GenCall score >0.15 required per call
Variant calling & QC: • Cluster file (GenTrain) separates AA/AB/BB genotype clusters per SNP • Sample-level QC: call rate >98%, heterozygosity within 3 SD of cohort mean • Imputation (optional): reference panel (1000 Genomes/TOPMed) extends coverage to ~40M variants via linkage disequilibrium
Key nutrition SNP panel: • MTHFR rs1801133 (C677T): folate/homocysteine metabolism • FTO rs9939609: obesity/satiety signaling • APOE rs429358/rs7412: haplotype defines ε2/ε3/ε4, lipid response to dietary fat • CYP1A2 rs762551: caffeine metabolism rate (fast vs slow metabolizer) • TCF7L2 rs7903146: type 2 diabetes / carbohydrate response • ALDH2 rs671: alcohol metabolism (East Asian flush variant)
A raw genotype call is clinically meaningless without functional annotation. Each SNP is cross-referenced against GWAS Catalog effect sizes, ClinVar pathogenicity, and enzyme kinetic studies to translate "TT at rs1801133" into "35% residual MTHFR enzyme activity, elevated homocysteine risk."
MTHFR C677T (Ala222Val): • CC (wild-type): full enzyme activity, standard 400 µg DFE/day folate sufficient • CT (heterozygous): ~65% activity, mild homocysteine elevation under low-folate diet • TT (homozygous variant, ~10-15% of Europeans): ~30% activity, thermolabile enzyme, requires 600-800 µg DFE/day + active 5-MTHF form supplementation
FTO rs9939609 (intronic, regulates IRX3/IRX5 in hypothalamus): • AA risk genotype: ~3 kg higher average body weight, blunted post-meal satiety signaling • Diet interaction: risk conferred is attenuated by high physical activity and high-protein diets
APOE genotype (defined by 2 SNPs): • ε4 carriers: hyperresponsive LDL-C to dietary saturated fat; benefit disproportionately from low-SFA, Mediterranean-pattern diets • ε2 carriers: risk of type III hyperlipoproteinemia with combined dyslipidemia triggers
CYP1A2 rs762551 (*1F allele): • AA (fast metabolizer): caffeine cleared efficiently, minimal cardiovascular risk from 3+ cups/day • C-carriers (slow metabolizer): caffeine half-life nearly doubled, associated with elevated MI risk at high intake
Dietary Reference Intakes (DRI) are population-average recommendations. Nutrigenomic modeling perturbs these baselines using SNP effect sizes to generate an individualized target range — the core computational step that turns genotype into an actionable diet prescription.
Individualized target = Baseline DRI × (1 + Σ βᵢ × riskAlleleᵢ)
Where βᵢ is the per-allele effect size from meta-analyzed GWAS/candidate-gene studies, bounded to avoid extrapolation beyond observed dose-response ranges.
Worked example — folate for MTHFR 677TT: • Baseline RDA: 400 µg Dietary Folate Equivalents (DFE)/day • TT genotype effect: enzyme activity reduced to ~30% → functional folate need increases ~1.5-2× • Adjusted target: 600-800 µg DFE/day, with preference for pre-reduced 5-methyltetrahydrofolate (5-MTHF) over synthetic folic acid, which requires MTHFR-independent but still enzymatic reduction
Worked example — saturated fat ceiling for APOE ε4: • Baseline AHA guidance: <10% of calories from saturated fat • ε4 hyperresponsiveness: LDL-C rises disproportionately per gram SFA • Adjusted target: <7% of calories from saturated fat, increased MUFA/PUFA substitution
The algorithm additionally incorporates non-genetic covariates (age, sex, BMI, baseline labs) since gene-diet effect sizes are typically estimated in mixed-covariate cohorts — genotype shifts the target, but does not override baseline physiology.
Nutrigenomic adjustments are directional and bounded, not absolute prescriptions — effect sizes for most SNPs explain only 1-3% of inter-individual variance in the nutrient response, so genotype refines but does not replace standard clinical nutrition assessment.
Before a 12-week clinical trial confirms real-world response, a physiologically-based pharmacokinetic-style model simulates the expected trajectory of key biomarkers (plasma folate, homocysteine, LDL particle number, postprandial glucose) under the proposed genotype-matched diet, allowing rapid what-if testing of adherence scenarios.
The simulator uses a simplified 4-compartment ODE model (gut lumen → portal plasma → hepatic pool → peripheral tissue) parameterized from published folate and lipid kinetic studies:
d[Plasma]/dt = k_abs×[Gut]×adherence − k_up×[Plasma] + k_release×[Liver] d[Homocysteine]/dt = k_prod − k_MTHFR_effective×[5-MTHF_plasma]
Where k_MTHFR_effective is scaled by the individual's genotype-derived enzyme activity fraction (e.g. 0.3 for TT). Adherence enters as a multiplicative dose-fraction on intake, letting users see how partial compliance (e.g. 70% vs 100%) attenuates the predicted biomarker response — a key patient-communication tool.
Similarly, an FTO/TCF7L2-informed postprandial glucose module adjusts insulin sensitivity parameters in a minimal Bergman model to project glucose AUC reduction under a lower-glycemic-load meal pattern.
The nutrigenomic pipeline is only as good as its real-world validation. A 12-week follow-up blood panel compares observed biomarker change against the model's prediction, and the correlation across a validation cohort is the ultimate test of whether genotype-informed nutrition outperforms generic dietary advice.
Design: single-arm pre/post genotype-matched diet intervention, 12 weeks, n=64 (MTHFR TT subgroup) plus n=51 (APOE ε4 subgroup), fasting labs at baseline, week 6, week 12.
MTHFR TT arm outcomes: • Plasma homocysteine: 14.2 → 9.8 µmol/L (mean, target <10 µmol/L achieved in 78% of participants) • RBC folate: 2.1-fold increase from baseline with 5-MTHF (active form) vs 1.3-fold with folic acid in a genotype-mismatched comparator arm — demonstrating the clinical value of matching folate form to enzyme genotype
APOE ε4 arm outcomes: • LDL-C: −11% at week 12 on <7% SFA precision diet vs −4% in a standard <10% SFA advice arm • LDL particle number (NMR) fell proportionally more than LDL-C mass, consistent with reduced small dense LDL
Model-observed correlation: across all tracked biomarkers, Pearson r=0.81 between the week-12 model projection and the measured value, with systematic under-prediction of homocysteine response in participants reporting adherence >90% — suggesting the linear adherence-dose term modestly underestimates high-compliance benefit.
A 2022 meta-analysis (Fenech et al., framework review) found genotype-tailored folate dosing reduced homocysteine 30-40% more effectively than uniform population-level folate fortification in MTHFR TT carriers specifically — the clearest evidence to date that nutrigenomic stratification changes clinical outcomes, not just theoretical risk scores.